A drop of blood could spot a deadly liver disease in newborns
NCT ID NCT03898765
First seen Jul 31, 2026 · Last updated Jul 31, 2026
Summary
This trial is testing whether a dry blood spot test—using a tiny sample from a newborn's heel—can screen for biliary atresia, a serious liver condition that blocks bile flow. The test measures certain biomarkers (direct bilirubin, γ-GT, and MMP-7) that may be elevated in affected babies. The goal is to enable earlier diagnosis and treatment, which could improve survival. The study will include newborns born in Shanghai.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Dry blood spot screening measuring biomarkers (direct bilirubin, γ-GT, MMP-7)
- What this could lead to
- If successful, this could lead to a routine newborn screening test that catches biliary atresia early, potentially saving lives through timely surgery.
- What could go wrong
- This is an early-stage diagnostic study, and the test may not be accurate enough for widespread use. False positives or negatives could occur, and more research is needed before it becomes standard.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Expected to start
-
Apr 2019
An estimate. Start dates often move.
- Finished
-
Dec 2021
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Neonates born in Shanghai Exclusion Criteria: * Subjects who do not agree with study protocol * Subjects who join other clinical trials
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Biliary atresia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai Xinhua Hospital, affiliated to Shanghai Jiao Tong University, School of Medicine
Shanghai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can stem cells help infants with biliary atresia avoid a liver transplant?
- What drives a rare liver disease in newborns? a genetic deep dive aims to find out
- Robotic surgery from miles away: could remote operations match On-Site care?
- AI assistant could spot hidden liver and pancreas cancers earlier
- Diaper photos may spot hidden liver disease in babies
- Could daily antibiotics shield babies from Post-Surgery infections?